Candel Therapeutics, Inc. (the Company or Candel) (Nasdaq: CADL), a
clinical stage biopharmaceutical company focused on developing
viral immunotherapies to help patients fight cancer, today will
present two posters during the 2023 Society for Immunotherapy of
Cancer (SITC) Annual Meeting in San Diego focused on the enLIGHTEN™
Discovery Platform.
“We aim to leverage artificial intelligence and machine learning
to expedite various aspects of drug discovery and development,”
said Paul Peter Tak, MD, PhD, FMedSci, President and Chief
Executive Officer of Candel. “Combined with our strong focus on
human biology for drug discovery and our deep experience with
herpes simplex virus as therapeutic vectors, Candel is poised to
expand its portfolio of promising viral immunotherapy candidates
and create value through discovery partnerships.”
The first poster titled ‘Development of enLIGHTEN™ Alpha-201
herpes simplex viral vectors encoding payloads targeting the tumor
microenvironment’ reports preclinical characterization of the
enLIGHTEN™ viral chassis Alpha-201. Profiling of biological
responses to Alpha-201 unveiled its potential to orchestrate
changes in the tumor microenvironment, supportive of effective
anti-tumor immune responses to immune checkpoint inhibitor (ICI)
treatment. In preclinical models, Alpha-201 displayed enhanced
peripheral blood mononuclear cell-mediated cancer cell killing and
immune activation when armed with certain immunostimulatory payload
combinations which was predicted in silico using the enLIGHTEN™
Advanced Analytics suite. These data validate Candel’s novel
approach for in silico prediction of payload combinations and
selection of indication-specific payloads with anti-tumoral
activity using human datasets as a tool to accelerate, improve and
de-risk certain aspects of the development of transformative viral
immunotherapies.
“Tumor resistance to immunotherapy is driven by multiple
mechanisms, which are heterogeneous in nature,” said Francesca
Barone, MD, PhD, Chief Scientific Officer at Candel. “By
interrogating human datasets and generating predictions on
tumor-specific mechanisms of progression, enLIGHTEN provides a
unique opportunity to predict optimal gene payload combinations to
arm viral vectors, enabling the design of multimodal therapeutics
with greater potential to overcome tumor resistance.”
The second poster titled ‘A novel viral immunotherapeutic
targeting the CD47/SIRPα axis demonstrates potent anti-tumor
effects’ describes the design of the first experimental agent based
on the enLIGHTEN™ Discovery Platform, Alpha-201-macro1. This
investigational agent is comprised of an immunostimulatory and
oncolytic engineered viral chassis armed with a novel gene payload
that is designed to interfere with the CD47/SIRPα pathway.
“Therapies targeting the CD47/SIRPα pathway have shown promising
clinical results in solid and hematological malignancies; however,
efficacy is often hindered by systemic toxicity,” said Anne Diers,
PhD, Senior Director of Research at Candel Therapeutics. “The
Alpha-201-macro1 preclinical data presented today support the
utility of local delivery of an immunologically active, multimodal
agent as a potential alternative to systemic therapy. We are
excited to leverage the enLIGHTEN™ Discovery Platform to optimize
the immunostimulatory payload of this agent for activation of
innate immune surveillance with the goal of maximizing its
therapeutic potential.”
Further details from the posters are available on the Candel
website at: www.candeltx.com/media
About the
enLIGHTEN™ Discovery
Platform
Candel’s enLIGHTEN™ Discovery Platform is a systematic,
iterative HSV-based discovery platform leveraging human biology and
advanced analytics to create new viral immunotherapies for solid
tumors. In October 2022, the Company announced a discovery
collaboration with the University of Pennsylvania Center for
Cellular Immunotherapies to identify how viral immunotherapy could
enhance the efficacy of CAR-T cell therapy in solid tumors. The
enLIGHTEN™ Discovery Platform is designed to deconvolute the
complexity of the tumor microenvironment to identify druggable
properties that correlate with clinical outcomes. These discoveries
are translated into optimized multi-gene payloads of tumor
modulators that are tailored for specific indications, disease
stage, and rationally designed therapeutic combinations.
About Candel Therapeutics
Candel is a clinical stage biopharmaceutical company focused on
developing off-the-shelf viral immunotherapies that elicit an
individualized, systemic anti-tumor immune response to help
patients fight cancer. Candel’s engineered viruses are designed to
induce immunogenic cell death through direct viral-mediated
cytotoxicity in cancer cells, thus releasing tumor neo-antigens
while creating a pro-inflammatory microenvironment at the site of
injection. This leads to in situ vaccination against the injected
tumor and uninjected distant metastases.
Candel has established two clinical stage viral immunotherapy
platforms based on novel, genetically modified adenovirus and
herpes simplex virus (HSV) gene constructs, respectively. CAN-2409
is the lead product candidate from the adenovirus platform and is
currently in ongoing clinical trials in non-small cell lung cancer
(NSCLC) (phase 2), borderline resectable pancreatic cancer (phase
2), and localized, non-metastatic prostate cancer (phase 2 and
phase 3). CAN-3110 is the lead product candidate from the HSV
platform and is currently in an ongoing investigator-sponsored
phase 1 clinical trial in recurrent high-grade glioma. In addition,
Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative
HSV-based discovery platform leveraging human biology and advanced
analytics to create new viral immunotherapies for solid tumors.
For more information about Candel,
visit: www.candeltx.com
Forward-Looking Statements
This press release includes certain disclosures that contain
“forward-looking statements,” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including,
without limitation, express or implied statements regarding the
timing and advancement of current and future development programs,
including the timing and availability of additional data, the
possibility to use preclinical readouts as predictor of clinical
response, the potential for the enLIGHTEN™ Discovery Platform to
expedite drug discovery and development and expand Candel’s
portfolio of viral immunotherapy candidates and expectations
regarding the therapeutic benefit of its product candidates and
experimental agents, including Alpha-201. The words “may,” “will,”
“could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, those risks and
uncertainties related to the timing and advancement of current and
future development programs; that final data from our pre-clinical
studies and completed clinical trials may differ materially from
reported interim data from ongoing studies and trials; expectations
regarding the therapeutic benefit of the Company’s programs; the
Company’s ability to efficiently discover and develop product
candidates; the Company’s ability to obtain and maintain regulatory
approval of product candidates; the Company’s ability to maintain
its intellectual property; the implementation of the Company’s
business model, and strategic plans for the Company’s business and
product candidates, and other risks identified in the Company’s SEC
filings, including the Company’s most recent Quarterly Report on
Form 10-Q filed with the SEC, and subsequent filings with the SEC.
The Company cautions you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. The Company disclaims any obligation to publicly update
or revise any such statements to reflect any change in expectations
or in events, conditions, or circumstances on which any such
statements may be based, or that may affect the likelihood that
actual results will differ from those set forth in the
forward-looking statements. Any forward-looking statements
contained in this press release represent the Company’s views only
as of the date hereof and should not be relied upon as representing
its views as of any subsequent date.
Media ContactAljanae ReynoldsDirectorWheelhouse
Life Science Advisorsareynolds@wheelhouselsa.com
Investor ContactSylvia
WheelerPrincipalWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Candel Therapeutics (NASDAQ:CADL)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Candel Therapeutics (NASDAQ:CADL)
Historical Stock Chart
Von Mai 2023 bis Mai 2024